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Evidence of altered mucosa-
associated and fecal microbiota 
composition in patients with 
Irritable Bowel Syndrome
Johanna Sundin ?ǡ ?ǡAziz ?ǡƤNordlander ?ǡ ?ǡPolster ?ǡǤǤHu   ?ǡ 
ǤHugerth   ?ǡǤǤPennhag ?ǡEngstrand ?ǡTörnblom ?ǡ
Magnus Simrén ?ǡ ?ǡ ? & Lena Öhman ?ǡ ?ǡ ?ȗ
Altered bacterial composition and small intestinal bacterial overgrowth (SIBO) may be associated 
ȋȌǤǦ
ȋ
ȌǤ
ǡ ? ?Ǧ
ǦǤǡ
ǤǤ
Ƥǡǡơ
(n = ? ?Ȍȋ= ? ?ȌǤƤƤ
Ǥ	ƤơǡǦ
Ƥȋ ? 
and/or CH ? ≥ ? ?ȌǤǤ
demonstrates that alterations in the bacterial composition of the sigmoid colon of IBS patients were 
ǤƪǦ
ǡ
Ǥ
Irritable bowel syndrome is a chronic functional bowel disorder which afects around 6% of the population1. he 
pathophysiology of IBS is multifactorial and has been suggested to include an altered bacterial composition of 
the gut. Additionally, small intestinal bacterial overgrowth (SIBO), characterized by abnormally high amounts of 
colonizing bacteria in the small bowel, has been suggested as an important feature in at least subsets of patients2.
Even though the reported prevalence of SIBO among IBS patients is highly variable, several studies, including 
a recent meta-analysis2, have shown a high prevalence of SIBO in IBS patients3–5. he current gold standard for 
diagnosing SIBO is bacterial culture of small intestinal aspirate6, but the majority of bacterial strains requires 
unknown growth conditions and have therefore not been cultured7, which could lead to false negative results. 
However, the majority of studies reporting high prevalence of SIBO in IBS patients are based on results from 
glucose and lactulose breath tests2, measuring the amount of hydrogen and methane produced by bacteria ater 
digestion of ingested fermentable sugars, but do not include quantiication of bacteria. he above mentioned 
discrepancies in evaluation methods most likely explain the conlicting reports of prevalence of SIBO reported 
in IBS8.
he majority of previous studies evaluating gut microbiota composition of IBS patients have focused on the 
fecal and colonic compartments. For example, previous results from our group showed a subset of IBS patients 
with an altered bacterial composition in feces9,10, and that the mucosa-associated bacterial composition of the 
colon in IBS patients was linked to mucosal low-grade immune activation11,12. However, so far only two previous 
 ?Ǥǡ
ǡ
ǡǤ ?Ǥǡ
ǡ
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studies have evaluated the small intestinal bacterial composition of IBS patients, demonstrating conlicting 
results13,14. To this date no studies have evaluated both the luminal and mucosa-associated bacterial composition 
in the upper and lower gastrointestinal tract in IBS patients.
In this study we hypothesized that IBS patients have an altered bacterial composition in the small and/or large 
intestine, which in turn is associated with the symptom pattern and the host´s intestinal immune response. hus, 
the aim of this study was to determine the bacterial composition of fecal samples and biopsies from the small and 
large intestine, respectively, and to determine the link to symptom pattern and intestinal immune response in 
IBS patients. Further, this study aimed to explore the consistency between evaluation methods for SIBO and to 
explore the accordance between breath test results and intestinal bacterial composition.
Results
Ǥ In total, 17 IBS 
patients and 20 healthy subjects were included in the study. Among patients, 2 were deined as IBS-C, 7 as IBS-D, 
8 as IBS-nonCnonD (Table 1). hree patients were deined as having post-infectious IBS (PI-IBS) ater a self-re-
ported bout of gastroenteritis. here were no diferences in age, BMI or gender between patients and healthy 
subjects (Table 1). As expected HADS and IBS-SSS scores were signiicantly higher in patients than in healthy 
subjects (Table 1).
Intestinal bacterial composition is highly dependent on sample type and regional localiza-
Ǥ A principal component analysis (PCA) demonstrated that the general bacterial composition difered 
distinctly between samples obtained from feces, duodenum and the sigmoid colon, in IBS as well as in healthy 
(Fig. 1a). Shannon diversity (number of OTUs and evenness) was signiicantly lower in the duodenum compared 
to the sigmoid colon (p < 0.01) in both IBS and healthy (Fig. 1b), and the beta-diversity was structurally diferent 
between sample types and regional localization (p < 0.001) (Fig. 1c). he bacterial compositional diference of 
sample types and regional localization was further conirmed by orthogonal partial least squares-discriminant 
analysis (OPLS-DA) of IBS (R2 = 0.80, Q2 = 0.77) and healthy (R2 = 0.85, Q2 = 0.80) (Fig. 1d), respectively. he 
OPLS-DA also identiied the bacteria (n = 26 and n = 29, respectively) that contributed the most to the separation 
among IBS and healthy (Fig. 1e). he majority of bacterial taxa driving the separation of bacterial composition 
between the sample type and regional localization were the same for IBS and healthy, whereas a few bacterial taxa 
were exclusive for IBS (Supplementary Table 3).
	Ǥ A 
PCA of the fecal bacterial composition did not show any major diferences between IBS and healthy (Fig. 2a). 
However, beta-diversity difered between IBS and healthy (p < 0.001) (Fig. 2b). Further, an OPLS-DA (VIP > 1.4) 
demonstrated that the fecal bacterial proile of IBS difered from healthy (p = 0.016, R2 = 0.60, Q2 = 0.43), (Fig. 2c) 
and identiied that the majority of bacteria (n = 18) that contributed the most to this separation, were found in 
higher relative abundance in IBS compared to healthy (Fig. 2d, Supplementary Table 4). Further, an OPLS-DA 
demonstrated diferent fecal bacterial compositions (R2 = 0.69, Q2 = 0.39) between IBS subtypes (IBS-D, IBS-C 
and IBS-nonCnonD), (Fig. 2e), and identiied the bacteria (n = 16) that contributed the most to the separation. 
For instance, IBS-D patients had higher relative abundance of Faecalibacterium whereas IBS-nonCnonD patients 
had higher abundance of the Bacteroides (Fig. 2f). Additionally, patients with HAD anxiety scores ≥8 (n = 6), 
showed a diferent fecal bacterial composition (R2 = 0.67, Q2 = 0.60) compared to those with HAD anxiety scores 
<8 (Fig. 2g,h). Patients with severe IBS symptoms showed similar fecal bacterial proile compared to those with 
mild/moderate IBS symptoms (R2 = 0.43, Q2 = 0.19).
Ǧǡǡ-
Ǥ Based on PCA there was no overall diference in the 
mucosa-associated bacterial composition of the sigmoid colon of IBS compared to healthy (Fig. 3a). However, 
OPLS-DA (VIP >1.4) demonstrated that the mucosa-associated bacterial composition of the sigmoid colon 
IBS HS
p-value*(n = 17) (n = 20)
Sex (F/M) 12/5 9/11 0.18
Age (years) 30 (26–36) 26 (21–35) 0.11
BMI 22.4 (20.6–26.6) 22.0 (20.7–24.3) 0.51
HADS score¤ 11 (6–20) 7 (3–10) 0.008
Anxiety¤ 7 3 0.14
Depression¤ 3 0 0.09
IBS-SSS score 277 (233–299) 11 (1–18) <0.0001
Subtype (IBS-D/IBS-C/IBS-nonCnonD) 7/2/8 N/A
Table 1. Clinical and Demographic factors of IBS patients and healthy subjects (HS). Abbreviations: 
IBS-C = Constipation predominant IBS. IBS-SSS = IBS Symptom Severity Score. IBS-D = Diarrhea 
predominant IBS. HADS = Hospital Anxiety and Depression. ¤Based on HADS Anxiety ≥8, Based on HADS 
Depression >10. Data shown as median (range 25–75%), Mann Whitney U Test between groups.
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Figure 1. he fecal and mucosa-associated bacterial proiles of the small intestine and colon of IBS patients and 
healthy subjects. Proiles of the relative abundance of fecal bacteria (grey circles) and the mucosa-associated 
bacteria from the sigmoid colon (blue squares) and the duodenum (pink circles) of irritable bowel syndrome 
(IBS, n = 16) and healthy subjects (n = 19). (a) Principal component analysis (PCA) of IBS and healthy. 
(b) Shannon diversity of the bacterial composition of fecal samples and the mucosal-associated bacterial 
composition of the sigmoid colon and the duodenum of IBS and healthy. (c) Beta-diversity of the bacterial 
composition of fecal samples and the mucosa-associated bacterial composition of the sigmoid colon and 
the duodenum of IBS and healthy. (d) Multivariate orthogonal partial least squares-discriminant analysis 
(OPLS-DA) of IBS and healthy, respectively, with bacteria as X-variables and fecal samples, biopsies from the 
sigmoid colon and biopsies from the duodenum, respectively, as Y-variables. (e) Loading scatter plot from the 
OPLS-DA showing the separation between fecal samples and the mucosa-associated bacterial composition of 
the sigmoid colon and the duodenum, respectively, with the bacterial composition. Green squares represent 
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difered between IBS and healthy (p = 0.001, R2 = 0.82, Q2 = 0.64), and identiied the bacterial genera (n = 17) 
that contributed the most to the separation (Fig. 3b). he loading column plot revealed lower relative abundance 
of Coprococcus 1 and higher relative abundance of Candidatus Soleaferrea in IBS compared to healthy (Fig. 3c, 
Supplementary Table 3). According to OPLS-DA, the diferent IBS subtypes displayed similar mucosa-associated 
bacterial proiles of the sigmoid colon (R2 = 0.34, Q2 = 0.19), whereas patients with HAD anxiety scores ≥8 
(n = 6), had a diferent bacterial composition of the sigmoid colon compared to those with HAD anxiety scores 
<8 (R2 = 0.59, Q2 = 0.47) (Fig. 3d,e). Additionally, patients with severe symptoms displayed a diferent bacterial 
proile compared to patients with mild/moderate symptoms (R2 = 0.91, Q2 = 0.81) (Fig. 3f). In general, the load-
ing column plot display that the majority of the bacteria (n = 14) that contributed the most to the separation were 
found in higher relative abundance in patients with severe symptoms (Fig. 3g). In contrast, the mucosa-associated 
duodenal bacterial composition did not difer between IBS and healthy (OPLS-DA; VIP >1.4, p = 0.40, R2 = 0.29, 
Q2 = −0.09) (Fig. 3h, Supplementary Table 3) and no link to IBS subtypes or severity of IBS symptoms was 
demonstrated (OPLS-DA, VIP >1.4; R2 = 0.46, Q2 = −0.06 and R2 = 0.35, Q2 = 0.27, respectively). However, 
patients with HAD anxiety scores ≥ 8 (n = 4) displayed a diferent duodenal bacterial composition compared to 
those with HAD anxiety scores <8 (n = 8), (R2 = 0.83, Q2 = 0.67) (Fig. 3i,j).
Bacterial cultures demonstrate similar prevalence of SIBO and bacterial growth in IBS patients 
Ǥ None of the patients or healthy met the golden standard for SIBO ≥105 CFU/ml 
anaerobic mixed bacterial lora15, neither in aspirate nor in duodenal biopsy cultures (Fig. 3k). Further, although 
there were individual variations in growth of opportunistic commensals, independent of sample type, there was 
no diference in bacterial growth between IBS and healthy (Fig. 3k).

Ǥ Independent of breath test based deinition the frequency of patients meeting the glucose 
and lactulose breath tests based SIBO criteria, indicating proximal and distal SIBO, respectively, was similar to 
healthy (Table 2). Moreover, when observed over time, no signiicant diferences in neither H2 nor CH4, ater 
glucose or lactulose intake were recorded between IBS and healthy (Fig. 4a) and IBS patients with high baseline 
values of either H2 or CH4 (262 (202–280)) displayed similar IBS symptom severity according to the IBS-SSS 
compared to patients with normal baseline values (285 (227–314)), (p = 0.32).
Investigation of potential links between H2 and CH4 levels and the bacterial composition were performed 
on individuals with a positive breath test using the baseline value (H2 and/or CH4 ≥ 15 ppm) (Table 2). When 
comparing individuals with a positive breath test (n = 12), (H2 and/or CH4 ≥ 15 ppm) and a negative breath test 
at baseline (n = 25) (Table 2), the bacterial composition difered between the two groups in the duodenal mucosa 
(R2 = 0.70, Q2 = 0.46) and sigmoid colonic mucosa (R2 = 0.73, Q2 = 0.48), but not in feces (R2 = 0.61, Q2 = 0.37) 
(Fig. 4b). he bacterial genera that contributed the most to the separation between the groups are shown in 
(Fig. 4c).
ƤǤ We fur-
ther evaluated fecal and mucosa-associated bacteria of the colon in relation to the colonic immune response 
of the host. A clustered correlation matrix analysis of mucosal antimicrobial gene expression and the bacteria 
that contributed the most to the separation between IBS and healthy, and thus characterized the two groups 
were performed. Numerous correlations between antimicrobial gene expression and mucosa-associated as well 
as fecal bacteria were identiied in IBS. In the colonic mucosa of IBS patients, the majority of the analyzed bacteria 
were positively correlated to the expression of many antimicrobial genes (n = 30) (Fig. 5a), and the fecal bacteria 
were either positively or negatively correlated to the expression of several antimicrobial genes (n = 21) (Fig. 5c). 
Substantially fewer correlations between the expression of antimicrobial genes (n = 2 and n = 11, respectively) 
and mucosa-associated or fecal bacteria were found in healthy (Fig. 5b,d).
Discussion
his exploratory study demonstrated an altered bacterial composition in the colon of IBS patients compared to 
healthy subjects, where diferences in both fecal and mucosal samples were detected. Additionally, anxiety, as 
well IBS subtype and IBS symptom severity were associated to intestinal bacterial composition. Further, a link 
between the IBS-speciic colonic bacterial signature and expression of antibacterial genes was demonstrated. 
Despite lack of evidence supporting bacterial alterations in the small intestine or elevated prevalence of SIBO in 
IBS patients, elevated baseline values of breath methane and hydrogen were associated with the intestinal bacte-
rial composition.
his is the irst study making use of a broad range of analytical methods to comprehensively explore and 
compare small intestinal bacterial overgrowth (SIBO), using diferent deinitions, with the mucosa-associated 
and luminal bacterial composition in both the small and large intestine of IBS patients and healthy subjects. he 
unique combination of sample types in this study, representing diferent regional localizations, allowed us to 
demonstrate that altered mucosa-associated and fecal bacterial composition speciically located in the colon in 
IBS patients. Contrary, both small intestinal bacterial composition and the prevalence of SIBO were similar in IBS 
bacteria which relative abundance contributed the most to the separation in the bacterial composition of 
the diferent sample types of both IBS and healthy, while blue circles are exclusively shown to contribute 
to the separation of the bacterial compositions of the diferent sample types of IBS or healthy, respectively. 
* = Signiicant diference between sample type according to the Kruskal-Wallis test. U. = Unclassiied.
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Figure 2. Fecal bacterial proiles of IBS patients and healthy subjects. Fecal bacterial composition of IBS 
patients (n = 16, dark grey squares) and healthy subjects (n = 19, light grey circles). (a) Principal component 
analysis (PCA) of IBS and healthy. (b) Beta-diversity analysis of IBS and healthy. (c) OPLS-DA showing the 
separation between IBS and healthy, respectively, and the fecal bacterial composition. Multivariate analysis was 
performed with fecal bacteria as X-variables and IBS and healthy, respectively, as Y-variables. (d) OPLS-DA 
loading column plot of the fecal bacteria that contributed the most to the separation between IBS and healthy. 
(e) Score scatter plot from the OPLS-DA showing the separation between the diarrhea predominant (IBS-D, 
n = 6; yellow large circle), constipation predominant (IBS-C, n = 2, green small circle) and the nonCnonD-IBS 
(n = 8, dark red square) subtypes, respectively, and the fecal bacterial composition. Multivariate analysis was 
performed with fecal bacteria as X-variables and IBS subtypes, respectively, as Y-variables. (f) OPLS-DA loading 
scatter plot of the fecal bacteria that contributed the most to the separation between IBS subtypes. (g) Score 
scatter plot from the OPLS-DA showing the separation between IBS patients with anxiety (n = 6; dark green 
squares), and without anxiety (n = 10, light green circles), respectively, and the fecal bacterial composition. 
Multivariate analysis was performed with fecal bacteria as X-variables and IBS patients with and without 
anxiety, respectively, as Y-variables. (h) OPLS-DA loading scatter plot of the fecal bacteria that contributed the 
most to the separation between IBS patients with and without anxiety. * = Signiicant diference between groups 
according to the Kruskal-Wallis test or the Mann-Whitney test. U. = Unclassiied.
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Figure 3. Mucosa-associated bacterial proiles and SIBO evaluation of IBS patients and healthy subjects. 
(a) PCA of the mucosa-associated bacterial composition of the colon of IBS and healthy. (b) Score scatter 
plot from the Multivariate orthogonal partial least squares-discriminant analysis (OPLS-DA) showing the 
separation between IBS (n = 16, light blue squares) and healthy (n = 19, dark blue cicles), respectively, and 
the mucosa-associated bacterial composition in the colon. (c) OPLS-DA loading column plot of the mucosa-
associated bacteria of the colon that contributed the most to the separation between IBS and healthy. (d) Score 
scatter plot from the OPLS-DA showing the separation between IBS patients with anxiety (n = 6; dark green 
squares), and without anxiety (n = 10, light green circles), respectively, and the mucosa-associated bacterial 
composition in the colon. (e) OPLS-DA loading scatter plot of the mucosa-associated bacteria of the colon 
that contributed the most to the separation between IBS patients with and without anxiety. (f) Score scatter 
plot from the OPLS-DA showing the separation between symptom severity (IBS-SSS) based IBS subsets, mild/
moderate IBS (IBS-SSS < 300, n = 4; orange circles) and severe IBS (IBS-SSS > 300, n = 12, green squares) 
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patients compared to healthy subjects. his was the case even though presence of bacterial alterations in diferent 
parts of the gastrointestinal tract and SIBO were evaluated with several methods such as culture independent 16S 
analysis, bacterial cultures and glucose and lactulose breath tests. While all of the above mentioned methods have 
their limitations, the combination enhances the robustness of our results.
his study conirms that the global bacterial composition in diferent parts of the gastrointestinal tract in both 
IBS patients and healthy subjects are speciic to sample type and regional location16. Moreover, our results sug-
gest that bacteria of the mucosa and feces, respectively, could potentially be diferently linked to IBS symptoms. 
Hence, fecal bacterial composition of IBS patients was linked to fecal stool form, which forms the basis for bowel 
habit-based IBS subtyping (IBS-D, IBS-C and IBS-nonCnonD)17 and thus conirm associations between stool 
consistency and bacterial composition previously shown in healthy subjects18. While the reasons for this link 
requires further investigation, one potential explanation could be that delayed transit is associated with enhanced 
proteolytic bacterial fermentation of proteins, associated with the formation of microbial cell components19. 
Moreover, the mucosa-associated bacteria, which are in close contact to host nerves and immune cells, were 
linked to IBS symptom severity. Potentially, this is a result of bacteria produced products that due to close proxim-
ity afect epithelial cells and trigger visceral pain responses either directly or through immune activation20,21. For 
instance, more severe symptoms were linked to reduced relative abundance of the Ruminococcaceae UCG-005 
genera, previously shown to be associated with a healthy intestine22. Additionally, as previously shown in feces11, 
anxiety in IBS was associated with the composition of the mucosa-associated and fecal bacteria.
he high resolution of the bacterial analyses together with discriminant analyses (OPLS-DA) in our study 
allowed identiication of signatures of fecal as well as sigmoid mucosa-associated bacteria, speciic for IBS patients. 
A feature of the fecal and mucosa-associated sigmoid bacterial signature of IBS patients was reduced relative 
abundance of bacteria belonging to the Ruminococcaceae family. Reduction of these bacteria has previously been 
associated with aberrant immune activation, such as exaggerated Toll-like receptor 2 (TLR-2) responses23 and 
reduced production of short chain fatty acids (SCFAs) which improve barrier integrity and has anti-inlammatory 
properties24. herefore, the low relative abundance of bacterial genera belonging to Ruminococcaceae shown in 
feces and in the sigmoid mucosa in IBS patients in this study suggests a potential underlying mechanism for the 
low grade inlammation previously shown in IBS25,26. Further, we conirmed previous reports of a subset of IBS 
patients with a diferent global fecal bacterial composition compared both to healthy subjects and to the remain-
ing IBS patients9–11, emphasizing the importance to take the heterogeneity among IBS patients into account.
To ensure comprehensive investigation of SIBO, we followed the European and North American consensus 
reports for evaluation of SIBO with breath tests27,28, and performed bacterial cultures of aspirate according to 
the current golden standard15, but additionally evaluated the full bacterial composition of the small intestine of 
IBS patients with culture independent 16S analysis. Contrary to some recent studies2,13, we could not detect any 
evidence for altered small intestinal bacterial composition or increased prevalence of SIBO in IBS, independent of 
deinition of SIBO. Potentially, the high prevalence of SIBO in previous reports may be a result of the fact that the 
majority of studies are based on breath tests2, which is an indirect test with numerous sources of error29. However, 
this exploratory study demonstrated a link between baseline concentration of hydrogen and methane measured 
with breath tests and the mucosa-associated bacterial composition of the duodenum and sigmoid colon, but not 
feces. As mucus-derived components provides an energy source for mucolytic bacteria, oten present in close 
contact to the mucosa30, the baseline results of the breath tests could potentially be a result of diversity between 
individuals regarding the composition of mucosal glycans or the mucolytic bacteria that ferment mucosal glycans.
In line with a previous study from our group12, this study conirms that there are links between the fecal and 
mucosa-associated bacterial proiles of IBS and the colonic expression of antibacterial genes. In this study the 
bacteria most important for characterizing IBS patients were associated to the gene expression of numerous 
antimicrobial genes, whereas only few associations were seen in the corresponding analyses of healthy subjects. 
However, our data do not allow us to conclude whether the altered bacterial composition is a cause or a conse-
quence of the host response, although it seem rather clear that these parameters are linked in the IBS patients, and 
possibly resulting in, or relecting, a destabilized intestinal microenvironment.
One of the limitations of this study is it’s the cross-sectional nature, since it is well known that intestinal bac-
terial composition luctuates over time31–33. However, this limitation is also true for the majority of studies of the 
bacterial composition and more importantly also for clinical investigations of SIBO in IBS9–11,34. Further, the rel-
atively small study cohort limits the strength of the conclusions to be drawn from the study. All study procedures 
were strictly standardized and the same researchers performed sample collection during all endoscopies, in order 
to limit variability of bacterial composition due to diferences in sample collection routines. Furthermore, the 
mucosa-associated bacteria composition of the duodenum is based on a relatively low number of sample reads, 
respectively, and the mucosa-associated bacterial composition of the colon. (g) OPLS-DA loading column plot 
of the mucosa-associated bacteria of the colon that contributed the most to the separation between IBS patients 
with severe symptoms compared to those with mild/moderate symptoms. (h) OPLS-DA score scatter plot of 
the mucosa-associated bacterial composition of the duodenum of IBS (n = 12, light blue squares) compared to 
healthy (n = 19, dark blue circles). (i) OPLS-DA score scatter plot depicting the association between IBS patients 
with anxiety (n = 4; dark green squares), and without anxiety (n = 8, light green circles), respectively, and the 
mucosa-associated bacterial composition in the duodenum. (j) OPLS-DA loading scatter plot of the mucosa-
associated bacteria of the duodenum that contributed the most to the separation between IBS patients with 
and without anxiety. (k) Proportions of bacterial growth in aspirates, duodenal biopsies and colonic biopsies, 
respectively in IBS (n = 16) and healthy (n = 19). * = Signiicant diference between groups according to the 
Mann-Whitney test or the Kruskal-Wallis test. U. = Unclassiied.
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which most likely relects the low bacterial load in this part of the small intestine31. However, to ensure that this 
did not have any major inluence on the results, all analyses were performed with cut-ofs of 1000 and 500 reads, 
respectively, and there were no major diferences in the results between these analyses. Another limitation is that 
patients were not included based on the updated ROME IV criteria, but on the ROME III criteria, making com-
parisons between this study and studies selecting patients according to the ROME IV criteria somewhat diicult. 
However, a study on a corresponding Swedish cohort has shown that most ROME III-positive IBS patients seek-
ing healthcare fulil the ROME IV criteria35.
To conclude, the indings of this unique study, evaluating both sample type and regional localization speciic 
bacterial composition alterations using several diferent methods, demonstrated alterations in the bacterial com-
position in the colon, but not in the small intestine of patients with IBS. Despite lack of evidence in this study 
for high prevalence of SIBO or small intestinal bacterial alterations of IBS patients, breath test results relected 
the intestinal bacterial composition. Further, this study demonstrated that bacterial alterations of the colon are 
associated to the intestinal immune response and also to psychological and gastrointestinal symptoms, indicating 
that the bacterial composition has a central role in IBS pathophysiology.
Method
Ǥ IBS patients who met the ROME III diagnostic criteria36 were 
recruited from the outpatient clinic at Sahlgrenska University Hospital Gothenburg, Sweden. Exclusion criteria 
included microscopic colitis, celiac disease, food allergies, or any other GI disease explaining the symptoms. 
Other exclusion criteria included abnormal results on standard screening laboratory tests, severe psychiatric, 
systemic or other chronic diseases, history of drug or alcohol abuse, and the inability to reliably respond to ques-
tionnaires in Swedish. Based on recorded bowel movements in a one-week stool diary, IBS patients were subtyped 
into diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), while IBS patients with mixed 
loose and hard stools (IBS-M) and those who had unsubtyped IBS (IBS-U) were grouped together (non-con-
stipation-non-diarrhea predominant, nonCnonD)36. Healthy subjects without gastrointestinal (GI) symptoms 
(assessed for seven days prior to inclusion with a GI symptom screening questionnaire), psychiatric, gastroin-
testinal, cardiac or metabolic diseases were included. IBS patients and healthy subjects were of Caucasian ethnic 
origin. Informed consent was obtained from all participants before any study-related procedures. We recorded 
the use of speciic diets and medications in all study subjects (Supplementary Table 1).
From all study subjects, biopsies were obtained from the second part of the duodenum and the sigmoid colon 
(25–35 cm proximal from the anus) by the same gastroenterologist (IA) using standard biopsy forceps without 
prior bowel preparation. Once collected all samples were handled by one researcher (JS), biopsies were immedi-
ately snap frozen in liquid nitrogen and stored at −80 °C until further analysis or placed in NaCl 0.9% solution 
and transferred within 2 h to microbiology for culture. Duodenal juice was aspirated prior to biopsy collection 
from participants where this was possible, i.e. where intestinal liquid was present and could be aspirated through 
the biopsy channel of the endoscope and collected in a sterile, DNA/RNA free, plastic tube and transferred within 
2 h to microbiology for culture. Fecal samples were collected by patients at home, immediately frozen in −20 °C 
and brought frozen to the laboratory where it was stored frozen in −80 °C until analysis. he study was approved 
by the Regional Ethical review Board in Gothenburg, and all subjects provided informed consent before any study 
related procedures were initiated. All experiments were performed in accordance with relevant guidelines and 
regulations.
Ǥ Cultures of aerobic and anaerobic bacteria were made on blood agar plates with 4% 
deibrinated horse blood in aerobic and anaerobic atmospheres of N2 and 10% CO2 at 37 °C. Selective culti-
vation of Gram-negative strains was performed on Drigalski agar under aerobic conditions. Yeast fungus was 
cultured on Sabouraud’s agar. he minimum incubation time was 48 h. Identiication of the microorganisms was 
based on colony characteristics, Gram staining, biochemical and chromatographic tests and Maldi-tof (Vitek-MS, 
Biomerieux). Quantification was performed by counting the number of colony-forming units (cfu/ml). 
Culture-veriied SIBO was deined as >105 cfu/ml of colonic bacteria according to the current golden standard15.
IBS (n = 17) HS (n = 20) p-value
Glucose Breath test
Fasting levels of H2 ≥ 15 ppm 2 3 >0.99
Fasting levels of CH4 ≥ 15 ppm 3 5 0.71
Rise of H2 or CH4 ≥ 20 above baseline within 90 min 0 0 N.A.
Lactulose Breath test
Fasting levels of H2 ≥ 15 ppm 1 3 0.61
Fasting levels of CH4 ≥ 15 ppm 1 3 0.61
Rise of H2 ≥ 20 ppm above baseline within 90 min 2 2 >0.99
Rise of CH4 ≥ 20 ppm above baseline within 90 min 1 0 0.44
Two distinct peaks of H2 or CH4 > 20 ppm 0 1 0.44
Table 2. IBS patients and healthy subjects (HS) with indication of small intestinal bacterial overgrowth 
according to diferent glucose and lactulose breath test based deinitions. N.A. = Non applicable; HS = Healthy 
Subjects.
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Ǥ Breath tests were performed ater at least one day with low iber diet, 
ater fasting overnight, a short resting period in the morning and ater careful brushing of the teeth. In addition, 
the subject was instructed not to consume any laxatives, bulking agents, or bile acid sequestrants the day before 
the test. If the irst baseline value exceeded 15 parts per million (ppm) for methane or hydrogen, the subject 
performed a mouthwash with tap water before the next baseline value was collected. If the subject had repeat-
edly high baseline values the subject was rescheduled for an examination another day, ater even more stringent 
instructions about preparation for the test, please see above, and ater 24 hours of iber-free diet. Subjects with 
high baseline values were rescheduled for a maximum of three visits. Ater recording two baseline values, subjects 
ingested 45 gram of glucose (Apoteket Produktion & Laboratorier, Sweden) in 300 ml tap water, or lactulose in 
the form of syrup (15 mL of syrup solution 670 mg/mL) (Laktulos Meda, Meda AB, Solna, Sweden), respectively. 
Hydrogen and methane gas in expired air was measured every 15 minutes during the following 120 (glucose) or 
180 (lactulose) minutes. he expired air was collected in a two-bag system (Quintron, Milwaukee, WI, USA) with 
Figure 4. Glucose or lactulose breath tests and their link to the bacterial composition. (a) Exhaled H2 and CH4 
over time, ater glucose and lactulose ingestion in IBS (n = 17, purple dotted line) and healthy (n = 20, black 
solid line). (b) Multivariate orthogonal partial least squares-discriminant analysis (OPLS-DA) score scatter plot 
of the bacterial composition of feces, the mucosa-associated bacterial composition in the colon and the mucosa-
associated bacterial composition in the duodenum of IBS and healthy with positive glucose or lactulose breath 
test (yellow squares) based on elevated baseline levels of H2 and/or CH4 (>15 ppm) compared to those with a 
negative test (purple circles). (c) OPLS-DA loading scatter plot showing the separation between IBS and healthy 
with positive fasting glucose or lactulose breath test compared to those with a negative test, and the bacterial 
composition of feces, the mucosa-associated bacterial composition in the colon and the mucosa-associated 
bacterial composition in the duodenum, respectively. Multivariate analysis was performed with bacteria as 
X-variables and IBS and healthy with a positive fasting breath test and those with a negative test at baseline, 
respectively, as Y-variables. * = Signiicant diference between those with a positive test compared to those with 
a negative test according to the Kruskal-Wallis test. U. = Unclassiied.
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a valve and mouthpiece. he exhaled air was then analyzed with a breath gas analyzer (BreathTracker, Digital 
microlyzer; Quintron, Milwaukee, WI, USA).
he breath test based deinitions of SIBO were based on either hydrogen or methane gas, respectively. he 
criteria were categorized into: (1) fasting levels (abbreviated fasting criteria of H2 or CH4 ≥ 15 ppm
37,38; (2) a rise 
of H2 or CH4 above baseline within 90 min (abbreviated increase criteria ≥20 ppm)
4,28,39; (3) for the lactulose 
breath test occurrence of double peaks (two distinct peaks or a characteristic double peak pattern >20 ppm on 
two consecutive readings40. he criteria for SIBO based on fasting breath levels were evaluated on the basis of the 
mean of the subject’s baseline values.
Ǥ DNA was extracted as previously 
described41 from feces (n = 35), duodenal biopsies (n = 28), sigmoid colonic biopsies (n = 35). In short, 1-step PCR 
procedure, ampliication was carried out by a high idelity proofreading polymerase for a total of 25 cycles 
(fecal samples) or 33 cycles (biopsies). For amplification of the sequencing libraries, forward primer 
5 ′ - C A AG C AG A AG AC G G C ATAC G AG AT- N 8 - G T C T C G T G G G C T C G G AG AT G T G TATA A 
GAGACAGGACTACHVGGGTATCTAATCC-3′ and reverse primer 5′AATGATACGGCGACCACCGAGATC- 
N8-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3′, where N8 repre-
sents an identifying 8-mer and the last 21 and 19 bases in each construct are the sequence speciic forward and 
reverse primers, respectively. Samples were then pooled to equimolar amounts and sequenced in parallel to whole 
bacterial genomes in a MiSeq instrument (Illumina Inc, San Diego, CA, USA). All controls from the extraction 
phase, as well as a negative PCR control have been submitted to PCR and consequently sequenced with the 
respective samples. Raw reads quality iltering and trimming, operational taxonomic units (OTU) clustering- and 
taxonomic assignment were performed as previously described41. α-diversity was evaluated on Shannon index 
and number of OTUs following rarefaction at 1099 sequences using the vegan R package. Beta-diversity (diversity 
between samples) was performed on Bray-Curtis index. Samples exceeding 10000 number of reads for fecal sam-
ples, 500 for duodenal biopsies and 15000 for colonic biopsies (Supplementary Table 2) were used. To ensure that 
the low number of reads did not impact the results from the duodenum, all analysis were additionally performed 
with only samples exceeding 1000 reads, which gave similar results in all analysis.
Figure 5. Clustered correlation matrix analysis between antibacterial gene expression and bacteria. Bacteria 
that were demonstrated to diferentiate between IBS and healthy were included in clustered correlation 
matrix analysis between antibacterial gene expression and bacteria. Correlation between (a) antibacterial 
gene expression and the mucosa-associated bacteria of IBS patients, (b) antibacterial gene expression and 
the mucosa-associated bacteria of healthy subjects (c) antibacterial gene expression and fecal bacteria of 
IBS patients, (d) antibacterial gene expression and the fecal bacteria of healthy subjects, are shown. Positive 
correlations are displayed in blue and negative correlations in red. Color intensity and the size of the circle are 
proportional to the correlation coeicients, only signiicant correlations are shown (p < 0.01).
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Ǥ Subjects completed a HADS and IBS-SSS to assess IBS and psychological symptom severity; 
for further details please see Supplementary Material.
ƤǤ Human Antibacterial Response RT² Proiler PCR 
Arrays (Cat No.ID PAHS-148Z, Qiagen) were conducted as previously described12, on biopsies from duodenum 
and colon. For further details please see Supplementary Material.
Ǥ Univariate analysis. Univariate analysis was performed in 
GraphPad Prism 6 (GraphPad Sotware, La Jolla, CA), Mann-Whitney was used to assess diferences between 
two groups and Kruskal-Wallis followed by Dunn’s test, was implemented for diferences between three groups. 
To evaluate diferences between the slopes of the curves of hydrogen and methane production over time in IBS 
patients and healthy subjects, linear regression analyses were performed on breath test data. If no other speciica-
tion, results are presented as median ± (25–75% percentile). Group diferences in beta-diversity were determined 
with PERMANOVA. Correlations between bacteria and antibacterial factors were analyzed with non-parametric 
Spearman correlations.
Multivariate analysis. Principal component analysis (PCA) was performed in R (Version 1.0.153) in the pack-
age ropls, to explore potential diferences in the global bacterial and antibacterial recognition factor proiles of 
groups. Clustered correlation matrix analysis was performed on gene expression data using the corrplot-package 
in R, calculations were performed with Spearman’s Rank Correlation Coeicient.
Multivariate factor orthogonal partial least squares-discriminant analysis (OPLS-DA) was performed to deter-
mine the most discriminatory X variables and to discriminate between healthy subjects and IBS patients as well 
as for IBS patients clustered into subtypes and subjects positive/negative for SIBO according to glucose or lactu-
lose breath tests, using SIMCA sotware (Version 14.1.3.0, copyright © MKS Data Analytics Solutions) based on 
bacterial composition (X variables). he R2 parameter represents the goodness of the it of the OPLS-DA with the 
best possible it being R2 = 1. When considering heterogeneous biological variables, a model would be considered 
to have a good it with an R2 ≥ 0.5. he Q2 parameter represents an estimate of the predictive ability calculated 
by cross-validation, with the best possible predictive ability of the OPLS-DA being Q2 = 1, a Q2 value > 0.4 is 
considered good for biological variables42. In multivariate analysis, outliers were removed if they were both above 
the Hotelling’s T2 Range Line of 95% and DModX DCrit (0.05). Loading column plots were generated to identify 
the X-variables most important for the discrimination between subsets. Variable Importance for the Projection 
(VIP) > 1.4 was used as the number of bacterial genera exceeded the number of subjects by far, except when 
identifying the bacterial genera that contributed most to the underlying variation in the X variables (bacterial 
genera) between the diferent IBS subtypes, few bacterial genera reach a VIP over 1.4, therefore VIP > 1.1 was 
used for these analysis. To reduce the risk of over-it post-hoc 100 permutation tests of the OPLS-DA models 
were performed and only models with permutation indices fulilling the post-hoc analysis criteria of R2 < 0.4 and 
Q2 < 0.05 were accepted43. he loading scatter plot may be superimposed over the OPLS-DA score scatter plot to 
see what X-variables are associated with which individuals. X variables localized further away from the center of 
the x-axis contribute more to the discrimination of the groups. he results are presented as a score scatter plot, a 
loading scatter plot or a loading column plot in which the stronger variables with a more reliable contribution to 
the model are those with a large column and small conidence interval. Multivariate diferences of X variables of 
the OPLS-DA, between patients and healthy subjects, were tested for signiicance using Hotelling’s T2 test in R 
(Package “Hotelling”).
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